Effect of Intranasal Insulin on LH Concentrations in Man

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Hypogonadotropic Hypogonadism

In brief

Over the last few years, studies have shown that men with type 2 diabetes sometimes develop a condition called hypogonadotrophic hypogonadism (HH). People with this condition produce little or no sex hormones. Obesity and metabolic syndrome are also associated with HH. Research suggests that insulin in the brain may benefit the glands that release these hormones. During this study, subjects will spray a small amount of insulin into their nose.This will increase insulin concentrations in the brain. The purpose of this study is to find out the effect of one dose of intranasal insulin on release of LH (a sex hormone) in obese diabetic men with HH.

Key facts

Study ID

NCT02154477

Run by

Texas Tech University Health Sciences Center

People needed

14

Starts

2014-12-01

Expected to finish

2017-12-01

Last updated by the study team

2019-08-13

Who can join

Age: 18 and older, up to 75. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Males age 18 to 75 years
• Obesity (BMI ≥30 kg/m2)
• Type 2 diabetes
• Hypogonadotropic hypogonadism defined as calculated free testosterone concentrations below 7 ng/dl along with normal or low LH concentrations

You may not qualify if…

• HbA1c>8.5%
• Use of preprandial insulin therapy
• Use of testosterone currently or in the past 4 months
• Use of over the counter health supplements which contain androgens
• Use of corticosteroids or narcotics in the past 3 months
• Coronary event or procedure(myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous twelve weeks
• Type I Diabetes
• Currently suffering from foot ulcer, significant periodontal disease or any other chronic infectious or inflammatory condition
• Hepatic disease (transaminase > 3 times normal) or cirrhosis
• Renal impairment (defined as glomerular filtration rate<30)
• HIV or Hepatitis C positive status
• Any other life-threatening, non-cardiac disease
• History of untreated severe obstructive sleep apnea(defined as apnea-hypopnea index ≥30)
• currently suffering from symptomatic depression, with or without treatment
• Use of an investigational agent or therapeutic regimen within 30 days of study
• Participation in any other concurrent clinical trial
• Pituitary tumor/damage/ other trophic hormone deficiency

Where it is running

• TTTUHSC-Permian Basin — Odessa, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.